The HSE has put a robust assessment process in place for new medicines, including cancer medicines, to ensure that the HSE can provide access to as many medicines as possible from within available resources. This includes a requirement for pharmaceutical companies to justify the proposed price for new medicines, as well as technical assessments by the National Centre for Pharmacoeconomics for medicines with significant budget implications. These assessments are used in decision making around new cancer medicines and during formal price negotiations with pharmaceutical companies. The NCCP has also put a multi-disciplinary Therapeutic Review Committee in place, specifically for the assessment of new, and on occasion existing, cancer medicines with regard to their benefits, costs and budget impact implications. In parallel to this, the NCCP has also instituted an Oncology Drug Management System for newly approved hospital based cancer medicines. This system is intended to ensure fair and equitable access across all hospitals, on a “money follows the patient” basis.